ArticleBMC musculoskeletal disorders2016
The tenocyte phenotype of human primary tendon cells in vitro is reduced by glucocorticoids.
Article in BMC musculoskeletal disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Long-term efficacy of point application therapy on different acupoints and durations in the treatment of asthma: a randomized controlled trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023Trial
- Effect of Ultrasonography-Guided Corticosteroid Injection vs Placebo Added to Exercise Therapy for Achilles Tendinopathy: A Randomized Clinical Trial.JAMA network open · 2022Trial
- Prolyl-Hydroxyproline Promotes Structural Matrix Organization in 3D Equine Tendon Proper and Peritenon Post-Injury Model.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2026Article
- Improving stem cell-derived extracellular vesicles for better tendon and tendon-to-bone junction regeneration: strategies and future directions.Stem cell research & therapy · 2026Review
- Dexamethasone treatment influences tendon healing through altered resolution and a direct effect on tendon cells.Scientific reports · 2024Article
- Upregulation of FABP4 induced inflammation in the pathogenesis of chronic tendinopathy.Journal of orthopaedic translation · 2024Article
- Effects of adipose-derived mesenchymal stem cell conditioned medium on human tenocytes exposed to high glucose.Therapeutic advances in musculoskeletal disease · 2024Article
- Engineered Decellularized Tendon Matrix Putty Preserves Native Tendon Bioactivity to Promote Cell Proliferation and Enthesis Repair.Journal of tissue engineering and regenerative medicine · 2023Article
- Article
- Allogeneic Serum and Macromolecular Crowding Maintain Native Equine Tenocyte Function in Culture.Cells · 2022Article
- Effects of long-term and high-dose administration of glucocorticoids on the cranial cruciate ligament in healthy beagle dogs.PloS one · 2022Article
- A combined physicochemical approach towards human tenocyte phenotype maintenance.Materials today. Bio · 2021Article
- Sustained Exposure of Substance P Causes Tendinopathy.International journal of molecular sciences · 2020Article
- Effects and Mechanism of Berberine on the Dexamethasone-Induced Injury of Human Tendon Cells.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Mitochondrial Dynamics Impairment in Dexamethasone-Treated Neuronal Cells.Neurochemical research · 2019Article
- Glutamate signaling through the NMDA receptor reduces the expression of scleraxis in plantaris tendon derived cells.BMC musculoskeletal disorders · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of corticosteroids (e.g., dexamethasone) as treatment for tendinopathy has recently been questioned as higher risks for ruptures have been observed clinically. In vitro studies have reported that dexamethasone exposed tendon cells, tenocytes, show reduced cell viability and collagen production. Little is known about the effect of dexamethasone on the characteristics of tenocytes. Furthermore, there are uncertainties about the existence of apoptosis and if the reduction of collagen affects all collagen subtypes.
methodsWe evaluated these aspects by exposing primary tendon cells to dexamethasone (Dex) in concentrations ranging from 1 to 1000 nM. Gene expression of the specific tenocyte markers scleraxis (Scx) and tenomodulin (Tnmd) and markers for other mesenchymal lineages, such as bone (Alpl, Ocn), cartilage (Acan, Sox9) and fat (Cebpα, Pparg) was measured via qPCR. Cell viability and proliferation was calculated using a MTS Assay. Cell death was measured by LDH assay and cleaved caspase-3 using Western Blot. Gene expression of collagen subtypes Col1, Col3 and Col14 was analyzed using qPCR.
resultsStimulation with Dex decreased cell viability and LDH levels. Dex also induced a significant reduction of Scx gene expression and a marked loss of fibroblast like cell shape. The mRNA for all examined collagen subtypes was found to be down-regulated. Among non-tendinous genes only Pparg was significantly increased, whereas Acan, Alpl and Sox9 were reduced.
conclusionsThese results indicate a Dex induced phenotype drift of the tenocytes by reducing scleraxis expression. Reduction of several collagen subtypes, but not cell death, seems to be a feature of Dex induced tissue degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.